|
The Directorate General of Foreign Trade (DGFT) has notified a new Standard Input Output Norm (SION) for metronidazole gel under the chemical & allied product category. This development comes as part of the ongoing efforts to facilitate ease of doing business and enhance the export competitiveness of India's pharmaceutical industry.
Metronidazole is an antibiotic used to treat skin infections, rosacea, mouth infections, including infected gums, dental abscesses, bacterial vaginosis and pelvic inflammatory disease.
The new norms set the following import-to-export item ratio for metronidazole gel USP 1%: for 55 gm pack of metronidazole gel USP 1% import item allowed: 0.561 gm of micronized metronidazole USP per pack.
For 60 gm tube of metronidazole gel USP 1% import item allowed: 0.612 gm of micronized metronidazole USP per pack.
This is aimed to bring clarity and facilitate ease in the manufacturing and export of metronidazole gel, a commonly used anti-parasitic and anti-bacterial medication, which is essential for various therapeutic treatments globally. The newly established SION will provide a standardized approach to input-output calculations for manufacturers and exporters of this pharmaceutical product.
The notification marks the inclusion of metronidazole gel USP 1% in the chemical & allied product group under the prescribed Standard Input Output Norms. This addition is expected to streamline production processes, improve accountability, and ensure consistency in the import of raw materials used in the manufacture of metronidazole gel for export. The inclusion of this SION also underlines the government’s ongoing commitment to fostering the growth of the pharmaceutical sector and supporting its competitive edge in the international market.
This development is a key part of India's broader strategy to increase pharmaceutical exports, a crucial area in the country’s trade balance. By defining specific norms for the import of ingredients, the government aims to ensure that manufacturers adhere to high standards while maintaining cost efficiency in the production of essential medicines.
|